Effect of rHDL on Atherosclerosis - Safety and Efficacy: THE ERASE TRIAL

Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound.

Currently available therapies to treat Acute Coronary Syndromes(ACS) have several limitations including; the relatively long treatment duration required before apparent significant benefit; the inability to achieve reversal of the atherosclerotic process; and poor patient compliance due to chronicity of therapy. This study will assess the effects of rHDL compared with placebo on indices of atherosclerosis progression and regression as assessed with intravascular ultrasound (IVUS) in patients after acute coronary syndromes (ACS).

Inclusion Criteria:

• Male or female 30 - 75 years of age
• Recent acute coronary syndrome, defined as unstable angina, non-Q wave myocardial infarction, or ST elevation indicative of myocardial infarction, within the last 14 days

Exclusion Criteria:

• >50% stenosis by visual angiographic estimation in the left main artery
• Renal insufficiency
• Severe liver disease
• Congestive heart failure as defined by the NYHA classification as functional Class III or Class IV
• Previous or planned coronary artery bypass surgery